Atossa Therapeutics shares are trading higher after the company and Quantum Leap announced an enrollment update for the (Z)-endoxifen arm of the ongoing I-SPY 2 clinical trial.
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics and Quantum Leap have announced an enrollment update for the (Z)-endoxifen arm of the ongoing I-SPY 2 clinical trial, leading to a rise in Atossa's share prices.
June 28, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics' shares are trading higher after an enrollment update for the ongoing I-SPY 2 clinical trial.
The enrollment update for the I-SPY 2 clinical trial is a positive development for Atossa Therapeutics, indicating progress in their research. This has led to increased investor confidence, reflected in the rise in share prices.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100